Friday, 6 September 2013

Histogen's receives patent for multipotent stem cells

Histogen, Inc., a regenerative medicine company developing therapies for conditions including hair loss and cancer, recently announced that the United States Patent & Trademark Office has issued patent 8,524,494, entitled "Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro" to the company.

The patent covers Histogen's method of triggering the de-differentiation of fibroblast cells into multipotent stem cells through low oxygen and special culture conditions. The resulting multipotent cells naturally secrete a variety of soluble and insoluble molecules that are the basis for Histogen's products.

"Histogen's process is uniquely capable of harnessing all of the benefits and excitement of stem cell therapies without any of the ethical, safety or sourcing concerns. Issuance of this patent adds great strength to our technology, and value to our partners and products." said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. 

You can read the whole announcement over Histogen's Website

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !